 |
Dendreon Receives FDA Acknowledgement of Complete Response |
Yesterday
|
 |
|
30 High Yielding Option Write Ideas for November Option Expiration Friday |
Yesterday
|
 |
|
Best Performing Stocks Since 3/9/09 and 10/9/07 |
11/12/2009
|
|
|
Unbiased Analysis on FITB, HCBK, ADSK, HBAN, FINL and DNDN Posted on WallStSense.com |
11/12/2009
|
 |
|
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization |
11/11/2009
|
|
|
Cramer's Mad Money - Hey Big Spenders (11/5/09) |
11/06/2009
|
|
|
Monday's Rx-Recap (11-02-09) |
11/03/2009
|
|
|
Dendreon's Provenge Looks Likely to Be Approved in Mid-2010 |
11/03/2009
|
|
|
BenchmarkJournal.com Issues Independent Review on FINL, FSLR, EWBC, FITB, BARE and DNDN |
11/03/2009
|
|
|
Dendreon Completes Submission of Biologics License Application for PROVENGE |
11/02/2009
|
|
|
Dendreon to Hold Conference Call on Wednesday, November 11, 2009 at 4:30 PM ET |
10/30/2009
|
|
|
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences |
10/29/2009
|
|
|
Upgrades: DNDN, DO, PNC |
10/23/2009
|
 |
|
BID, DGX, FO, CNW, DNDN and LAMR Receiving Professional Financial Coverage from RothmanResearch.com |
10/23/2009
|
|
|
Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter |
10/20/2009
|
 |
-$0.04 (-0.14%)
11:56PM (15 mins delay)
